Withdrawing Amantadine in Dyskinetic Patients with Parkinson Disease
Neurol 82:300-307, Ory-Magne, F.,et al, 2014
Short-Term Paroxetine Treatment Does Not Alter the Motor Response to Levodopa in PD
Neurol 64:1797-1798, Chung,K.A.,et al, 2005
Safety and Efficacy of Pallidal or Subthalamic Nucleus Stimulation in Advanced PD
Neurol 56:548-551, Volkmann,J.,et al, 2001
Investig of PDRG of UK into Excess Mortality Seen/Comb Levodopa & Selegiline Trmt in Pts with Early, Mild Parkinson's Dis
BMJ 316:1191-1196, Ben-Shlomo,Y.,et al, 1998
Tolcapone for Parkinson's Disease
The Medical Letter 40:60-61, , 1998
Catechol-O-Methyltransferase Inhibitors for Treatment of Parkinson's Disease
Lancet 351:1221-1222, Nutt,J.G., 1998
Serotonin Syndrome and the Combined Use of Deprenyl and An Antidepressant in Parkinson's Disease
Neurol 48:1070-1077, Richard,I.H.,et al, 1997
Complications of Chronic Levodopa Therapy; Long-term Efficacy of Drug Holiday
Neurol 31:473-476, Koller,W.C.,et al, 1981
Distinguishing Neuroimaging Features in Patients Presenting with Visual Hallucinations
AJNR 37:774-781, Winton-Brown, T.T.,et al, 2016
Clinical Features of Dopamine Agonist Withdrawal Syndrome in a Movement Disorders Clinic
JNNP 84:130-135, Pondal, M.,et al, 2013
Neurostimulation for Parkinsons Disease with Early Motor Complications
NEJM 368:610-622, Rau, W.,et al, 2013
Dopamine Agonist Withdrawal Syndrome in Parkinson Disease
Arch Neurol 67:58-63, Rabinak,C. &Nirenberg,M., 2010
Long-Term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease
Arch Neurol 66:563-570, Parkinson Sutdy Group CALM Cohort Investigators, 2009
Sexual Function in Men and Women With Neurological Disorders
Lancet 369:512-525, Rees,P.M.,et al, 2007
Levodopa Addiction in Idiopathic Parkinson Disease
Neurol 65:1508, Borek,L.L &Friedman,J.H., 2005
Levodopa and the Progression of Parkinson's Disease
NEJM 351:2498-2508, The Parkinson Study Group, 2004
Subthalamic DBS Replaces Levodopa in Parkinson's Disease
Neurol 58:396-401, Vingerhoets,F.J.G.,et al, 2002
Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease Progression
JAMA 287:1653-1661, Parkinson Study Group, 2002
Quetiapine for L-Dopa-Induced Psychosis in PD
Neurol 54:1538, Weiner,W.J.,et al, 2000
A Five-Year Study of the Incidence of Dyskinesia in Patients With Early Parkinson's Disease who were Treated with Ropinirole or Levodopa
NEJM 342:1484-1491, Rascol,O.,et al, 2000
Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease
NEJM 340:757-763,801, The Parkinson Study Group, 1999
Recent Advances, Neurology
BMJ 319:362-366, Larner,A.J.&Farmer,S.F., 1999
An Algorithm (Decision Tree) for the Management of Parkinson's Disease:Trtm Guidelines
Neurol 50:S1-S57, Olanow,C.W.&Koller,W.C., 1998
Practice Styles of US Compared to UK Neurologists
Neurol 50:1661-1668, Vickrey,B.G.,et al, 1998
Acute Delirium After Withdrawal of Amantadine in Parkinson's Disease
Neurol 50:1456-1458, Factor,S.A.,et al, 1998
Managing the Neuropsychiatric Symptoms of Parkinson's Disease
Neurol 50:S33-S38, Lieberman,A., 1998
Early Dopaminergic Drug-Induced Hallucinations in Parkinsonian Patients
Neurol 51:811-814, Goetz,C.G.,et al, 1998
Parkinson's Disease
NEJM 339:1044-1053,1130-1143, Lang,A.E.&Lozano,A.M., 1998
Low-Dose Clozapine Improves Dyskinesias in Parkinson's Disease
Neurol 48:658-662, Durif,F.,et al, 1997
Gabapentin for Parkinsonism:A Double-Blind Placebo-Controlled, Crossover Trial
Am J med 102:60-66, Olson,W.L.,et al, 1997
Managing the Late Complications of Parkinson's Disease
Neurol 49:549-557, Waters,C.H., 1997
Reversible Parkinsonism and Cognitive Impairment with Chronic Valproate Use
Neurol 47:626-635, Armon,C.,et al, 1996
Nonmotor Fluctuations in Patients with Parkinson's Disease
Neurol 47:1180-1183, Hillen,M.E.&Sage,J.I., 1996
Drug Treatment of Parkinson's Disease
BMJ 310:575-579, Quinn,N., 1995
Low-Dose Clozapine in the Treatment of Levodopa-Induced Mental Disturbances in Parkinson's Disease
Neurol 45:432-434, Rabey,J.M.,et al, 1995
Psychosis in Advanced Parkinson's Disease:Treatment with Ondansetron, a 5-HT3 Receptor Antagonist
Neurol 45:1305-1308, Zoldan,J.,et al, 1995
Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994
Levodopa, Melanoma, and Parkinson's Disease
Neurol 43:674-677, Weiner,W.J.,et al, 1993
Acute Respiratory Failure from Dopamine Agonist Withdrawal
Neurol 42:1843-1844, Riley,D.E.,et al, 1992
Olanzapine in the Treatment of Dopaminomimetic Psychosis in Patients with Parkinson's Disease
Neurol 47:1085-1087, Wolters,W.Ch.,et al, 1992
Early Development of Levodopa-Induced Dyskinesias and Response Fluctuations in Young-Onset Parkinson's Disease
Neurol 41:202-205, Kostic,V., 1991
Neuroleptic Malignant Synd in Parkinson's after Withdrawal or Alteration of Dopaminergic Therapy
Arch Int Med 151:794-796, Keyser,D.L.&Rodnitzky,R.L., 1991
Movement Disorders in Alcoholism:A Review
Neurol 40:741-746, Neiman,J.,et al, 1990
Dose-Dependent Memory Impairment in Parkinson's Disease
Neurol 39:438-440, Huber,S.J.,et al, 1989
Continuous Levodopa Infusions to Treat Complex Dystonia in Parkinson's Disease
Neurol 39:888-891, Sage,J.I.,et al, 1989
Dystonia in Parkinson's Disease:Clinical & Pharmacological Features
Ann Neurol 23:73-78, Poewe,W.H.,et al, 1988
Does Levodopa Aggravate Parkinson's Disease
Neurol 38:1410-1416, Blin,J.,et al, 1988
Forms of Dystonia in Patients with Parkinson's Disease
Neurol 37:1009-1011, Kidron,D.&Melamed,E., 1987
Initiation of Levodopa Therapy in Parkinsonisn Patients Should be Delayed Until the Advanced Stages of the Disease
Arch Neurol 43:402-407, Melamen,E., 1986